Loading...

PE/Cyanine7 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-67_PECyanine7_CD8a_Antibody_1_071124
C57BL/6 mouse splenocytes were stained with anti-mouse CD3ε (clone 145-2C11) FITC and anti-mouse CD8a (clone 53-6.7) PE/Cyanine7 (left) or rat IgG2a, κ PE/Cyanine7 isotype control (right).
  • 53-67_PECyanine7_CD8a_Antibody_1_071124
    C57BL/6 mouse splenocytes were stained with anti-mouse CD3ε (clone 145-2C11) FITC and anti-mouse CD8a (clone 53-6.7) PE/Cyanine7 (left) or rat IgG2a, κ PE/Cyanine7 isotype control (right).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Save
100721 25 µg ¥12,110
100722 100 µg ¥35,250
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  2. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  3. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  4. Jarick KJ, et al. 2018. Front Immunol. 9:1468. PubMed
  5. Seo JB, et al. 2019. Nat Metab. 1:86. PubMed
  6. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  7. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  8. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  9. Schnell A, et al. 2021. Cell. 184:6281. PubMed
  10. Fu A, et al. 2022. Cell. 185:1356. PubMed
  11. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  12. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  13. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  14. Poh AR, et al. 2022. Cell Rep. 41:111479. PubMed
  15. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  16. Chen X, et al. 2022. J Extracell Vesicles. 11:e12279. PubMed
  17. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  18. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  19. Roh YJ, et al. 2023. Lab Anim Res. 39:2. PubMed
  20. Giannou AD, et al. 2023. Immunity. 56:125. PubMed
  21. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  22. Wang C, et al. 2023. Exp Mol Med. 55:347. PubMed
  23. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  24. Georgiev GI, et al. 2022. Cell Chem Biol. 29:811. PubMed
  25. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  26. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  27. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
  28. Axelrod ML, et al. 2022. Nature. 611:818. PubMed
  29. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  30. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  31. Li L, et al. 2023. iScience. 26:106095. PubMed
  32. Liu N, et al. 2023. Cell Death Dis. 14:170. PubMed
  33. Cheng K, et al. 2023. Small. 19:e2300125. PubMed
  34. Li G, et al. 2023. Cell Death Dis. 14:185. PubMed
  35. Guo D, et al. 2023. Cell Biosci. 13:51. PubMed
  36. Wang Y, et al. 2023. Front Bioeng Biotechnol. 11:1128268. PubMed
  37. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  38. Sun R, et al. 2023. PLoS One. 18:e0282722. PubMed
  39. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  40. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  41. Lechuga-Vieco AV, et al. 2020. Sci Adv. 6:eaba5345. PubMed
  42. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  43. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  44. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  45. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  46. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  47. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  48. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  49. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  50. Tello‐Lafoz M, et al. 2017. Sci Rep. . 10.1038/s41598-017-16370-w. PubMed
  51. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  52. Ma F, et al. 2020. Cell Death Dis. 1.172222222. PubMed
  53. Baram T, et al. 2021. Cells. 10:. PubMed
  54. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  55. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  56. Hu J, et al. 2021. Sci Adv. 7:. PubMed
  57. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  58. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  59. Saito S, et al. 2020. Nutrients. 12:. PubMed
  60. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  61. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  62. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  63. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
  64. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  65. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  66. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  67. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  68. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  69. Wu FTH, et al. 2019. Br J Cancer. 120:196. PubMed
  70. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  71. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  72. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  73. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  74. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  75. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  76. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  77. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  78. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  79. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  80. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  81. Neubert K, et al. 2014. J Immunol. 192:5830. PubMed
  82. Sakthivel P, et al. 2014. PLoS One. 9:100970. PubMed
  83. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  84. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  85. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  86. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  87. Guo HF, et al. 2021. Commun Biol. 4:482. PubMed
  88. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  89. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  90. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  91. Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
  92. Amor C, et al. 2020. Nature. 583:127. PubMed
  93. Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed
  94. Szafran BN, et al. 2021. Chemical Research in Toxicology. 34(6):1556-1571. PubMed
  95. Li J, et al. 2020. Cancer Discov. . PubMed
  96. Wei SC, et al. 2020. Cancer Discov. . PubMed
  97. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  98. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  99. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  100. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  101. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  102. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  103. Wei M, et al. 2014. Protein Eng Des Sel. 27:289. PubMed
  104. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  105. Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
  106. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  107. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  108. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  109. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  110. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  111. Köchl R, et al. 2020. Elife. 9:00. PubMed
  112. Daniel CJ, et al. 2022. Mol Cancer Res. 20:1151. PubMed
  113. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  114. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  115. Sullivan B, et al. 2015. PLoS Pathog. 11:1004588. PubMed
  116. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  117. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  118. Dar HY, et al. 2018. Sci Rep. 8:2503. PubMed
  119. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  120. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  121. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  122. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  123. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  124. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  125. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  126. Lehmann M, et al. 2016. J Leukoc Biol. 99: 1057 - 1064. PubMed
  127. Li J, et al. 2018. Immunity. 49:178. PubMed
  128. Domingo–Gonzalez R, et al. 2020. eLife. 9:e56890.. PubMed
  129. Dar HY, et al. 2018. Bone Rep. 8:46. PubMed
  130. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  131. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  132. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  133. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  134. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
  135. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  136. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  137. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  138. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  139. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  140. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  141. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  142. Sapra L, et al. 2021. Sci Rep. 11:1807. PubMed
  143. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  144. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  145. Yang Y, et al. 2022. Elife. 11:. PubMed
  146. Kim S, et al. 2021. Elife. 10:. PubMed
  147. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  148. Abramowski P, et al. 2014. J Neuroimmunol. 274:111. PubMed
  149. Ariyoshi Y, et al. 2016. Gene Ther. 10.1038/gt.2016.7. PubMed
  150. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  151. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  152. Pietronigro E, et al. 2019. Sci Rep. 9:12055. PubMed
  153. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  154. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  155. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  156. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  157. Lang V, et al. 2021. Elife. 10:. PubMed
  158. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  159. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  160. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  161. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  162. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  163. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  164. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  165. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  166. Yabas M, et al. 2016. PLoS One. 11: 0146774. PubMed
  167. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  168. Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed
  169. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  170. Hsu M, et al. 2022. Nat Immunol. 23:581. PubMed
  171. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  172. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  173. Itoga M, et al. 2015. PLoS One. 10: e0123210. PubMed
  174. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  175. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  176. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  177. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  178. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  179. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  180. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  181. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  182. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  183. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  184. Bhatt D, et al. 2021. J Exp Med. 218:. PubMed
  185. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  186. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
  187. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
  188. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  189. Emily A Thompson et al. 2019. Cell reports. 26(11):2859-2867 . PubMed
  190. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  191. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  192. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  193. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  194. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  195. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  196. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  197. Silva DA, et al. 2019. Nature. 565:186. PubMed
  198. Lee YS, et al. 2019. Sci Adv. 5:eaaw4176. PubMed
  199. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  200. Rouse MD, et al. 2020. Front Microbiol. 11:414. PubMed
  201. Lopes N, et al. 2022. Elife. 11:. PubMed
  202. Tang S, et al. 2022. Virol J. 19:32. PubMed
  203. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  204. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  205. Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed
  206. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  207. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  208. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  209. Sharma R, et al. 2021. J Neuroinflammation. 72:18. PubMed
  210. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  211. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  212. Sheng J, et al. 2021. eLife. 10:00. PubMed
  213. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  214. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  215. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  216. Wang X, et al. 2022. Elife. 11:. PubMed
  217. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  218. Mykkänen O, et al. 2014. PLoS One. 9:114790. PubMed
  219. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  220. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  221. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  222. Goc J, et al. 2021. Cell. 184:5015. PubMed
  223. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  224. Goubet AG, et al. 2021. Cell Death Differ. 28:2276. PubMed
  225. Petty AJ, et al. 2021. JCI Insight. 6:. PubMed
  226. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  227. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  228. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  229. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  230. Plaza-Sirvent C, et al. 2021. Front Immunol. 12:705436. PubMed
  231. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
  232. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  233. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
  234. Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed
  235. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  236. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  237. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  238. Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed
  239. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  240. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_312760 (BioLegend Cat. No. 100721)
AB_312761 (BioLegend Cat. No. 100722)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
Hidden Names (DOES NOT SHOW ON TDS):
Lyt-2, Lyt 2, Ly2, Ly 2, CD8
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account